Thymalin

Wellness

Also known as: Thymus polypeptide complex, Thymus bioregulator

Limited Evidence

What is Thymalin?

A polypeptide complex isolated from bovine thymus gland, developed by the Khavinson group as a bioregulator for immune function. One of the most clinically-studied Khavinson bioregulators, used in Russia for immune support in elderly and cancer patients. Often paired with Epithalon in longevity protocols.

How it works

Thymalin is not a single defined peptide but a complex of thymic polypeptides believed to restore T-cell differentiation and maturation pathways that decline with age (thymic involution). The thymus atrophies significantly with age, reducing naive T-cell output and adaptive immune capacity. Thymalin is proposed to signal thymic epithelial cells to regenerate functional activity, restoring T-cell populations and immune surveillance. Specific active peptides within the complex are not fully characterized.

What marketers claim

  • completely reverses immune aging
  • eliminates all infections
  • equivalent to thymus transplantation
  • proven to extend lifespan by decades

What evidence supports

  • longitudinal study (Khavinson, 2003): elderly patients treated with Thymalin + Epithalon over 6–8 years showed reduced all-cause mortality vs untreated age-matched controls
  • clinical reports of improved T-cell counts in elderly patients with repeat dosing
  • reduces incidence of respiratory infections in elderly institutional patients per Russian clinical data

Research evidence

Key studies on Thymalin, summarized in plain language. This is not an exhaustive list — it highlights the most relevant findings.

Restoration of immune function and reduced mortality with thymalin plus epithalon: 6-year follow-up

2003Clinical Trialn = 266 elderly patients aged 60–74

Finding: Combined Thymalin + Epithalon over 6–8 years reduced all-cause mortality by 1.6–4.1× vs control groups; improvements in T-cell counts and NK activity documented.

Limitation: Non-randomized observational design, control group was age-matched patients not receiving peptides — confounding possible, from originating research group, not independently replicated.

Best for

longevity researchimmune function support

What to expect

Realistic timeline based on available research. Individual results vary.

10-day course

Standard Khavinson protocol: 1.0mg daily IM, repeated 2–3× per year.

Year 1–2

Russian clinical reports describe measurable T-cell improvement and reduced infection frequency over sustained course-based use.

Safety notes & concerns

Full safety guide →
  • longevity study lacked rigorous placebo controls and randomization by modern RCT standards
  • polypeptide complex of bovine origin — quality control, batch consistency, and theoretical prion contamination concerns
  • not available as an approved drug outside Russia
  • independent replication by non-Khavinson researchers has not been published
  • active peptide fractions responsible for efficacy not well characterized

Pairs well with

Use caution with

active autoimmune conditions — enhancing immune function could worsen autoimmunityactive cancer — non-specific immune stimulation in oncology carries theoretical risksimmunosuppressed transplant patients on antirejection therapy

Frequently asked questions

Is Thymalin the same as Thymosin Alpha-1?

No. Thymosin Alpha-1 is a single, well-defined 28-amino acid peptide approved as Zadaxin in several countries. Thymalin is a more complex, less well-characterized polypeptide mixture from bovine thymus. They both claim thymic mechanisms but are chemically and pharmacologically distinct.

Related wellness peptides

🧪

Take the Peptide Quiz

Get personalized recommendations

🔬

Stack Builder

Build a routine with Thymalin

Last updated: 2026-06-10

Medical Disclaimer

The information on this site is for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, or prevent any condition. Always consult with a qualified healthcare professional before starting any new supplement, peptide, or treatment protocol.